Table 2.
Serum markers of the study population
| Parameter | HCC (n = 70) mean ± SD median (IQR) | Cirrhosis (n = 38) mean ± SD median (IQR) | CHC or CHB (n = 30) mean ± SD median (IQR) | Control (n = 30) mean ± SD median (IQR) | P value (ANOVA) |
|---|---|---|---|---|---|
| Bilirubin (0.2–0.8 mg/dl) | 1.89 ± 2.66 0.9 (0.6–2.0) | 1.751 ± 1.71 1 (0.7–2.7) | 1.078 ± 1.65 0.7 (0.6–0.8) | 0.64 ± 0.25 0.6 (0.5–0.7) | 0.023 |
| AST (2–40 IU/l) | 117.45 ± 82.09 93 (65–139) | 98.98 ± 93.63 82 (51–108) | 103.22 ± 87.89 78 (53–118) | 33.17 ± 8.69 32 (26–40) | 0.0001 |
| ALT (2–40 IU/l) | 74.93 ± 57.46 61 (40–88) | 77.72 ± 83.7 1 53 (40–75) | 116.23 ± 96.29 100 (48–143) | 31.17 ± 9.47 33 (23–39) | 0.0001 |
| ALP (98–306 IU/l) | 315.49 ± 201.33 275 (160–481) | 291.12 ± 177.88 259 (155–369) | 210.60 ± 96.50 195 (158–279) | 141.7 ± 57.56 170 (135–228) | 0.0001 |
| Albumin (3.5–5.0 g/dl) | 3.252 ± 0.6342 3.1 (2.8–3.8) | 3.123 ± 0.6876 3.0 (2.6–3.5) | 3.783 ± 0.7120 3.8 (3.3–4.4) | 4.043 ± 0.4739 4.1 (3.7–4.4) | 0.0001 |
| PIVKA-II (ng/ml) | 101.07 ± 78.30 108.03 (15.85–170.24) | 2.45 ± 4.25 1.21 (00–2.23) | 1.50 ± 0.98 1.41 (0.78–2.06) | 0.79 ± 0.758 0.50 (00–1.50) | 0.0001 |
| AFP (ng/ml) | 2347.97 ± 7185.56 81 (12–791) | 28.25 ± 4.58 9 (4–21) | 7.84 ± 1.43 5 (3–9) | 4.45 ± 2.45 4 (2–6) | 0.019 |
AST aspartate aminotransferase, ALT alanine aminotransferase, ALP alkaline phosphatase, HCC hepatocellular carcinoma, CHC chronic hepatitis C, CHB chronic hepatitis B, ANOVA analysis of variance